← Back to list
Noninvasive Tests for Hepatic Fibrosis - Medicare Advantage (Revised)
Effective date
Jun 1, 2026
Identified
Jun 24, 2026
Summary
Humana Medicare Advantage has established new coverage criteria for noninvasive hepatic fibrosis tests, effective June 1, 2026. The policy covers FIB-4 index testing without restrictions and MRE with specific clinical criteria including chronic liver disease diagnosis or inconclusive FIB-4 results.
Get alerts when payers change rules like this one
We check Humana and other payers every day and email you when a change matches your specialty and state.
Get Humana alertsPolicy Monitoring is free. No card required.
What to do
Action · 3 steps
01Before June 1, 2026: Billing team must update prior authorization workflows for CPT 76391 (MRE) to verify patients meet specific criteria including chronic liver disease diagnosis, FIB-4 test results, absence of MRI contraindications, no recent hepatic fibrosis testing within 6 months, and unavailability of VCTE.
02Update encounter forms to remind providers to document these requirements.
03Claims not meeting criteria will be denied as not medically necessary.
Codes mentioned
8159976391
Original notice
Noninvasive Tests for Hepatic Fibrosis - Medicare Advantage (Revised)
mcp.humana.com · Always check the source before changing claims.
Related changes
See all Humana changes →Noninvasive Tests for Hepatic Fibrosis - Medicare Advantage (Revised)MediumEffective Aug 10, 2026 · Medicare AdvantageGene Expression Profiling for Cancer Indications - MEDICAID - FLORIDA (Revised)MediumEffective Oct 21, 2026 · MedicaidGene Expression Profiling for Cancer Indications - MEDICAID - VIRGINIA (Revised)HighEffective Oct 14, 2026 · MedicaidGenomic and Molecular Biomarker Testing for Cancer - MEDICAID - MICHIGAN (New)HighEffective Sep 23, 2026 · MedicaidBrowse every Humana change in the policy list